Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2023

Earnings Per Share [Abstract]

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share

The “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the respective periods indicated - is as follows:

	Three Months Ended March 31,
	2023			2022
Numerator
Net loss - before noncontrolling interest	$	(22,214	)	$	(19,633	)
Net loss attributable to noncontrolling interest		4,283			2,761
Net loss - as reported, attributable to PAVmed Inc.	$	(17,931	)	$	(16,872	)
Series B Convertible Preferred Stock dividends – earned	$	(74	)	$	(68	)
Net loss attributable to PAVmed Inc. common stockholders	$	(18,005	)	$	(16,940	)
Denominator
Weighted average common shares outstanding, basic and diluted		97,095,156			86,336,427
Net loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.18	)	$	(0.20	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.19	)	$	(0.20	)

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share

	March 31,
	2023		2022
Stock options and restricted stock awards		18,955,720		12,368,292
Series Z Warrants		11,937,450		11,937,450
Series B Convertible Preferred Stock		1,229,887		1,136,210
Total		32,123,057		25,441,952